Abstract

Germline gene therapy acts as a regenerative medicine leading to the evolution of biotechnology.  Targeting mutated reproductive cells, germline gene therapy prohibits the transfer of genetic disorders to the offspring. Researchers have demonstrated germline gene therapy studies utilizing various animal models as clinical support. In addition, germline gene therapy has induced the use of technology systems performing germline gene therapy mechanisms. The first transgenic primate was in fact produced by the Oregon Regional Primate Center, executing genetically modified embryos. Furthermore, fabricating mouse embryos into chimeras involving genetically modified embryonic stem cells is another documented study supporting germline gene therapy. Focalizing defected reproductive cells is advantageous about mitochondrial diseases. Replacing mutated mitochondrial genome reverts the invasive attack on the cytoplasm of an egg. Pronuclear transfer acts as a sufficient germline gene therapy technique correcting transmissible mitochondrial mutations. Implementing reformed technical support, CRISPR/Cas9 is a technology system that can correct mutations in the genome of organisms. Germline gene therapy techniques help regulate the consumption of inheritable diseases in offspring. Constructing evidential support leads to the permitted usage of germline gene therapy on human embryos. Examining the complexity of the dynamics of various genomes converts the impossible into probable.